Cargando…
Influence of renal complications on the efficacy and adverse events of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase: a single-centre, prospective study
OBJECTIVES: The study investigated whether renal complications affected the efficacy and safety of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase. METHODS: Fifty-seven patients with SLE (A: 30 cases with renal complication, B: 27 cases w...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453506/ https://www.ncbi.nlm.nih.gov/pubmed/26056606 http://dx.doi.org/10.1136/lupus-2015-000091 |
_version_ | 1782374459910389760 |
---|---|
author | Ishii, Sho Miwa, Yusuke Otsuka, Kumiko Nishimi, Shinichiro Nishimi, Airi Saito, Mayu Miura, Yoko Oguro, Nao Tokunaga, Takahiro Takahashi, Ryo Kasama, Tsuyoshi |
author_facet | Ishii, Sho Miwa, Yusuke Otsuka, Kumiko Nishimi, Shinichiro Nishimi, Airi Saito, Mayu Miura, Yoko Oguro, Nao Tokunaga, Takahiro Takahashi, Ryo Kasama, Tsuyoshi |
author_sort | Ishii, Sho |
collection | PubMed |
description | OBJECTIVES: The study investigated whether renal complications affected the efficacy and safety of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase. METHODS: Fifty-seven patients with SLE (A: 30 cases with renal complication, B: 27 cases without renal complications) were included. The presence of renal complications was defined as proteinuria ≥0.5 g/day and lupus nephritis on renal biopsy. Major outcome measures included SLE disease activity index (SLEDAI), steroid dose, serum anti-dsDNA Ab, C3 and creatinine (Cr) levels and estimated glomerular filtration rate (eGFR). The patient's background factors included age, gender, disease duration and ACE-I/angiotensin II receptor blocker and statin therapies. We compared these outcome measures pre treatment and after 1 year of treatment. RESULTS: The SLEDAI and serum C3 levels improved in both groups from pretreatment period to post-treatment period: from 7.2±5.0 to 2.8±2.3 in A and 6.4±3.8 to 2.4±2.2 in B, p<0.001, and from 65.9±24.6 to 77.7±18.2 mg/dL in A and 81.8±23.0 to 90.6±19.4 mg/dL in B, p=0.002, respectively. The anti-dsDNA antibody level was reduced, and the serum Cr and eGFR levels were slightly elevated. No patients developed end-stage renal failure that required artificial dialysis. CONCLUSIONS: Tacrolimus combination therapy had additive beneficial effects on reduced proteinuria and increased serum C3 levels in patients with SLE with renal complications during a maintenance phase. |
format | Online Article Text |
id | pubmed-4453506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-44535062015-06-08 Influence of renal complications on the efficacy and adverse events of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase: a single-centre, prospective study Ishii, Sho Miwa, Yusuke Otsuka, Kumiko Nishimi, Shinichiro Nishimi, Airi Saito, Mayu Miura, Yoko Oguro, Nao Tokunaga, Takahiro Takahashi, Ryo Kasama, Tsuyoshi Lupus Sci Med Lupus Nephritis OBJECTIVES: The study investigated whether renal complications affected the efficacy and safety of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase. METHODS: Fifty-seven patients with SLE (A: 30 cases with renal complication, B: 27 cases without renal complications) were included. The presence of renal complications was defined as proteinuria ≥0.5 g/day and lupus nephritis on renal biopsy. Major outcome measures included SLE disease activity index (SLEDAI), steroid dose, serum anti-dsDNA Ab, C3 and creatinine (Cr) levels and estimated glomerular filtration rate (eGFR). The patient's background factors included age, gender, disease duration and ACE-I/angiotensin II receptor blocker and statin therapies. We compared these outcome measures pre treatment and after 1 year of treatment. RESULTS: The SLEDAI and serum C3 levels improved in both groups from pretreatment period to post-treatment period: from 7.2±5.0 to 2.8±2.3 in A and 6.4±3.8 to 2.4±2.2 in B, p<0.001, and from 65.9±24.6 to 77.7±18.2 mg/dL in A and 81.8±23.0 to 90.6±19.4 mg/dL in B, p=0.002, respectively. The anti-dsDNA antibody level was reduced, and the serum Cr and eGFR levels were slightly elevated. No patients developed end-stage renal failure that required artificial dialysis. CONCLUSIONS: Tacrolimus combination therapy had additive beneficial effects on reduced proteinuria and increased serum C3 levels in patients with SLE with renal complications during a maintenance phase. BMJ Publishing Group 2015-05-29 /pmc/articles/PMC4453506/ /pubmed/26056606 http://dx.doi.org/10.1136/lupus-2015-000091 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Lupus Nephritis Ishii, Sho Miwa, Yusuke Otsuka, Kumiko Nishimi, Shinichiro Nishimi, Airi Saito, Mayu Miura, Yoko Oguro, Nao Tokunaga, Takahiro Takahashi, Ryo Kasama, Tsuyoshi Influence of renal complications on the efficacy and adverse events of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase: a single-centre, prospective study |
title | Influence of renal complications on the efficacy and adverse events of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase: a single-centre, prospective study |
title_full | Influence of renal complications on the efficacy and adverse events of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase: a single-centre, prospective study |
title_fullStr | Influence of renal complications on the efficacy and adverse events of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase: a single-centre, prospective study |
title_full_unstemmed | Influence of renal complications on the efficacy and adverse events of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase: a single-centre, prospective study |
title_short | Influence of renal complications on the efficacy and adverse events of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase: a single-centre, prospective study |
title_sort | influence of renal complications on the efficacy and adverse events of tacrolimus combination therapy in patients with systemic lupus erythematosus (sle) during a maintenance phase: a single-centre, prospective study |
topic | Lupus Nephritis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453506/ https://www.ncbi.nlm.nih.gov/pubmed/26056606 http://dx.doi.org/10.1136/lupus-2015-000091 |
work_keys_str_mv | AT ishiisho influenceofrenalcomplicationsontheefficacyandadverseeventsoftacrolimuscombinationtherapyinpatientswithsystemiclupuserythematosussleduringamaintenancephaseasinglecentreprospectivestudy AT miwayusuke influenceofrenalcomplicationsontheefficacyandadverseeventsoftacrolimuscombinationtherapyinpatientswithsystemiclupuserythematosussleduringamaintenancephaseasinglecentreprospectivestudy AT otsukakumiko influenceofrenalcomplicationsontheefficacyandadverseeventsoftacrolimuscombinationtherapyinpatientswithsystemiclupuserythematosussleduringamaintenancephaseasinglecentreprospectivestudy AT nishimishinichiro influenceofrenalcomplicationsontheefficacyandadverseeventsoftacrolimuscombinationtherapyinpatientswithsystemiclupuserythematosussleduringamaintenancephaseasinglecentreprospectivestudy AT nishimiairi influenceofrenalcomplicationsontheefficacyandadverseeventsoftacrolimuscombinationtherapyinpatientswithsystemiclupuserythematosussleduringamaintenancephaseasinglecentreprospectivestudy AT saitomayu influenceofrenalcomplicationsontheefficacyandadverseeventsoftacrolimuscombinationtherapyinpatientswithsystemiclupuserythematosussleduringamaintenancephaseasinglecentreprospectivestudy AT miurayoko influenceofrenalcomplicationsontheefficacyandadverseeventsoftacrolimuscombinationtherapyinpatientswithsystemiclupuserythematosussleduringamaintenancephaseasinglecentreprospectivestudy AT oguronao influenceofrenalcomplicationsontheefficacyandadverseeventsoftacrolimuscombinationtherapyinpatientswithsystemiclupuserythematosussleduringamaintenancephaseasinglecentreprospectivestudy AT tokunagatakahiro influenceofrenalcomplicationsontheefficacyandadverseeventsoftacrolimuscombinationtherapyinpatientswithsystemiclupuserythematosussleduringamaintenancephaseasinglecentreprospectivestudy AT takahashiryo influenceofrenalcomplicationsontheefficacyandadverseeventsoftacrolimuscombinationtherapyinpatientswithsystemiclupuserythematosussleduringamaintenancephaseasinglecentreprospectivestudy AT kasamatsuyoshi influenceofrenalcomplicationsontheefficacyandadverseeventsoftacrolimuscombinationtherapyinpatientswithsystemiclupuserythematosussleduringamaintenancephaseasinglecentreprospectivestudy |